Results 231 to 240 of about 153,000 (334)

Current and novel biomarkers in cardiogenic shock

European Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog   +5 more
wiley   +1 more source

Aptamer-Based Planar Electric Double-Layer Field-Effect Transistor: A Novel Approach for Sensitive Troponin I Sensing. [PDF]

Biosensors (Basel)
Hung SC, Lee YH.
europepmc   +1 more source

False-Positive Plasma Troponin I with the AxSYM Analyzer [PDF]

, 2000
Csaba Galambos, David S. Brink, Detlef Ritter, Hyung D. Chung, Michael H. Creer   +4 more
openalex   +1 more source

Furosemide‐hydration matching with RenalGuard® in decompensated heart failure: an alternative way to use diuretics and saline

ESC Heart Failure, EarlyView.
Massimo Mapelli, Filippo Maria Rubbo, Jeness Campodonico, Nicola Cosentino, Giancarlo Marenzi, Valentina Mantegazza, Filippo Trombara, Mateusz Sokolski, Piotr Ponikowski, Piergiuseppe Agostoni   +9 more
wiley   +1 more source

End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)

European Journal of Heart Failure, EarlyView.
End‐organ protective effect of serelaxin in patients with acute heart failure. CV, cardiovascular; HF, heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide. Abstract Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy.
Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry H. Greenberg, Gadi Cotter, Beth A. Davison, Iris E. Beldhuis, G. Michael Felker, Gerasimos Filippatos, Peter S. Pang, Piotr Ponikowski, Claudio Gimpelewicz, John R. Teerlink   +12 more
wiley   +1 more source

Impact of anesthetic technique on troponin I levels in pediatric cardiac surgery: a randomized clinical trial. [PDF]

Braz J Anesthesiol
Barelli JVG, Araujo DD, Zeferino SP, Dantas GM, Galas FB.   +4 more
europepmc   +1 more source

Cardiac Troponin I: A Marker for Post-Burn Cardiac Injury [PDF]

, 2000
Yi Ni Chen, Zhuo Ran Luo, Li Zeng, Min Wu, Yan Wu, Zhi Yu Lin   +5 more
openalex   +1 more source

Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow, Saeid Mirzai, Po‐Hao Chen, Mazen Hanna, W.H. Wilson Tang   +4 more
wiley   +1 more source

Effect of change of high-sensitivity troponin I assay on emergency department diagnosis and disposition of patients with possible acute coronary syndrome. [PDF]

Emerg Med Australas
Pickering JW, Kelland S, Williams O, Kim J, Aldous S, Joyce LR, Than MP.   +6 more
europepmc   +1 more source

Plasma Troponin T and Troponin I after Minimally Invasive Coronary Bypass Surgery [PDF]

, 2000
Siegmund Braun, A Barankay, Domenico Mazzitelli   +2 more
openalex   +1 more source